GRAIL Inc

GRAL

Market cap $4.08B

GRAIL, Inc. (GRAL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

In 2025, small-cap stocks underperformed. The Russell 2000 Index tracks the performance of 2,000 U.S. small-cap stocks, delivering a total return of around 13% in 2025.

MENLO PARK, Calif. , Dec. 15, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the 44th Annual J.P.

Early cancer detection is highly beneficial to sufferers, and Grail's Galleri test offers a solution. The company is the leader in the race for FDA approval, but it could benefit from being part of a larger company.

MENLO PARK, Calif. , Dec. 1, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 21,570 shares of GRAIL's common stock to 21 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.

Deutsche Bank appears to have set a high mark when it comes to forecasts for the S&P 500 in 2026, with a target of 8,000.

Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we're still in one of the best times in history to build wealth—especially if you think long-term and stay grounded in time-tested principles.

MENLO PARK, Calif. , Nov. 18, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, Dec. 2 at 3:00 p.m.

The cancer diagnostics specialist received two price target increases from separate analysts. One more than doubled his on the company.

Grail (GRAL) reported Q3 revenues of $36.2m, up 26% YoY, but continues to post significant losses and faces commercial challenges. Galleri test's PATHFINDER 2 study showed promising early cancer detection, yet questions remain about detection rates, pricing, and broad adoption, in my view. GRAL's stock has surged 185% since my last Hold call, despite lack of FDA approval and ongoing uncertainty around reimbursement, market size, and future profitability.